Zyn-Linkertm/Heparin Conjugate to Prevent Restenosis

Award Information
Agency:
Department of Health and Human Services
Branch:
N/A
Amount:
$686,168.00
Award Year:
1995
Program:
SBIR
Phase:
Phase II
Contract:
N/A
Agency Tracking Number:
19320
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Zynaxis, Inc.
371 Phoenixville Pike, Malvern, PA, 19355
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
N/A
Principal Investigator
 Gregory A Kopia
 (215) 889-2200
Business Contact
Phone: () -
Research Institution
N/A
Abstract
RISK ASSESSMENT FOR CHRONIC HEART DISEASE (CHD) USES INDIRECT ESTIMATES OF LDL CHOLESTEROL FROM TOTAL CHOLESTEROL, HDL AND VLDL ESTIMATES. NO CLINICAL ASSAY EXISTS TO QUANTITATE LDL DIRECTLY FROM SERUM. WE WILL USE A MODEL LDL DETERMINATION ASSAY USING PKH26-ZYN-LINKER LABELLED LDL PARTICLES (LDLS) TO QUANTIFY LDLS DIRECTLY RATHER THAN USING TRADITIONAL PRECIPITATION TYPE ASSAYS AND CALCULATED LDL VALUES. PHASE I'S SPECIFIC AIMS ARE: 1) COMPARISON OF PKH26 ZYN-LINKER LDLS TO COMMERICALLY AVAILABLE LDLS USING PHYSICAL PROPERTIES SUCH AS DENSITY, STABILITY, DYE TO PARTICLE RATIOS AND FUNCTIONAL PROPERTIES (E.G. LDL RECEPTOR BINDING); 2) GENERATION OF SOLID SUBSTRATES SPECIFICALLY ABLE TO REACT WITH NORMAL AND MUTANT LDL PARTICLES; AND 3) CREATION OF A MODEL ASSAY TO DIRECTLY MEASURE LDL CONCENTRATIONS. THE ASSAY WILL BE BASED UPON COMPETITIVE BINDING OF PATIENT LDLS WITH REAGENT PARTICLES AND SIGNALS WILL BE DETECTED USING SPECTROFLUOROMETRIC METHODS.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government